BioCentury
ARTICLE | Clinical News

5B1 antibody: Phase I start

February 1, 2016 8:00 AM UTC

This month, MabVax will start an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate HuMab-5B1 alone or with chemotherapy in up to 60 patients. ...